Technical Analysis for KIN - Kindred Biosciences, Inc.

Grade Last Price % Change Price Change
grade F 8.85 -3.49% -0.32
KIN closed down 3.49 percent on Monday, March 18, 2019, on 85 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical KIN trend table...

Date Alert Name Type % Chg
Mar 18 Wide Bands Range Expansion 0.00%
Mar 18 Oversold Stochastic Weakness 0.00%
Mar 15 Calm After Storm Range Contraction -3.49%
Mar 15 Oversold Stochastic Weakness -3.49%
Mar 14 Calm After Storm Range Contraction -2.85%
Mar 14 Oversold Stochastic Weakness -2.85%
Mar 13 New Downtrend Bearish -3.59%
Mar 13 Calm After Storm Range Contraction -3.59%
Mar 13 Narrow Range Bar Range Contraction -3.59%
Mar 13 NR7 Range Contraction -3.59%

Older signals for KIN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Kindred Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapies for pets. The company is pursuing small molecules and biologics that are in various stages of development for a range of indications in dogs, cats, and horses. Its products include CereKin, an oral interleukin-1 beta inhibitor for osteoarthritis pain and inflammation in dogs; AtoKin, a beef-flavored formulation of fexofenadine for atopic dermatitis in dogs; SentiKin, an oral analgesic formulation of flupirtine to manage post-operative pain in dogs and horses; KIND-007, an inhibitor of Bruton's tyrosine kinase; and KIND-006, an agent for gastrointestinal diseases in cats. The company also has a portfolio of other drugs and biologics under development, which comprise anti-IgE antibody for allergic and immune-mediated diseases; canine analog of Enbrel for inflammatory and autoimmune diseases; canine analog of Orencia for immune-mediated diseases; and KIND-504, a cancer vaccine. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.
Medicine Health Biotechnology Biopharmaceutical Cancer Pain Immunology Immune System Inflammation Osteoarthritis Atopic Dermatitis Gastrointestinal Diseases Immune Mediated Diseases Inflammatory And Autoimmune Diseases Atopy Etanercept Flupirtine Immunoglobulin E
Is KIN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 15.75
52 Week Low 8.05
Average Volume 252,805
200-Day Moving Average 12.0988
50-Day Moving Average 10.3853
20-Day Moving Average 10.1205
10-Day Moving Average 9.514
Average True Range 0.4604
ADX 30.75
+DI 9.6334
-DI 30.8487
Chandelier Exit (Long, 3 ATRs ) 9.9688
Chandelier Exit (Short, 3 ATRs ) 10.084299999999999
Upper Bollinger Band 11.6897
Lower Bollinger Band 8.5513
Percent B (%b) 0.1
BandWidth 31.010326
MACD Line -0.4254
MACD Signal Line -0.272
MACD Histogram -0.1535
Fundamentals Value
Market Cap 246.35 Million
Num Shares 27.8 Million
EPS -1.17
Price-to-Earnings (P/E) Ratio -7.56
Price-to-Sales 0.00
Price-to-Book 2.41
PEG Ratio -0.15
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.55
Resistance 3 (R3) 9.58 9.37 9.43
Resistance 2 (R2) 9.37 9.20 9.36 9.39
Resistance 1 (R1) 9.11 9.09 9.01 9.08 9.36
Pivot Point 8.91 8.91 8.86 8.89 8.91
Support 1 (S1) 8.65 8.73 8.54 8.62 8.34
Support 2 (S2) 8.44 8.62 8.43 8.31
Support 3 (S3) 8.18 8.44 8.27
Support 4 (S4) 8.15